Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

PEERLESS II-undersøgelsen

2. november 2026 opdateret af: Inari Medical

PEERLESS II: RCT af FlowTriever vs. Antikoagulation alene i lungeemboli

This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

1200

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Aalst, Belgien
        • Onze Lieve Vrouwziekenhuis
    • British Columbia
      • New Westminster, British Columbia, Canada, V3L 3W7
        • Royal Columbian Hospital
      • Surrey, British Columbia, Canada, V3V 1Z2
        • Surrey Memorial Hospital
      • Vancouver, British Columbia, Canada, V5Z 1M9
        • Vancouver General Hospital
      • Aarhus, Danmark, 8200
        • Aarhus University Hospital
    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35243
        • Brookwood Medical Center
      • Birmingham, Alabama, Forenede Stater, 35205
        • UAB Division of Cardiovascular Disease
    • California
      • Pasadena, California, Forenede Stater, 91105
        • Huntington Memorial Hospital
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • University of Colorado, Denver
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06520
        • Yale University
    • Florida
      • Largo, Florida, Forenede Stater, 33770
        • HCA FL Largo Medical Center
      • Orlando, Florida, Forenede Stater, 32803
        • AdventHealth Orlando
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Emory University
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Northwestern University
    • Michigan
      • Lansing, Michigan, Forenede Stater, 48910
        • McLaren Greater Lansing
    • Missouri
      • Kansas City, Missouri, Forenede Stater, 64111
        • Saint Luke's Hospital of Kansas City
      • Springfield, Missouri, Forenede Stater, 65804
        • Mercy Hospital Springfield
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68105
        • Nebraska Medical Center
    • New Jersey
      • Camden, New Jersey, Forenede Stater, 08103
        • Virtua Health
    • New York
      • Buffalo, New York, Forenede Stater, 14203
        • SUNY, The University of Buffalo/Gates Vascular
      • New York, New York, Forenede Stater, 10075
        • Northwell Health
      • Rochester, New York, Forenede Stater, 14642
        • University of Rochester Medical Center
      • Stony Brook, New York, Forenede Stater, 11794
        • Stony Brook University Hospital
      • The Bronx, New York, Forenede Stater, 10467
        • Montefiore Medical Center
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45219
        • University of Cincinnati Medical Center
      • Cleveland, Ohio, Forenede Stater, 44195
        • The Cleveland Clinic Foundation
      • Columbus, Ohio, Forenede Stater, 43210
        • Ohio State University - Wexner Medical Center
    • Pennsylvania
      • Bethlehem, Pennsylvania, Forenede Stater, 18015
        • St. Luke's University Hospital
      • Erie, Pennsylvania, Forenede Stater, 16507
        • UPMC Hamot
      • Erie, Pennsylvania, Forenede Stater, 16505
        • AHN Saint Vincent Hospital
      • Harrisburg, Pennsylvania, Forenede Stater, 17101
        • UPMC Harrisburg
      • Philadelphia, Pennsylvania, Forenede Stater, 19144
        • Thomas Jefferson University
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • The University of Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • UPMC Heart and Vascular Institute
      • Pittsburgh, Pennsylvania, Forenede Stater, 15212
        • Allegheny Health Network Research Institute
      • York, Pennsylvania, Forenede Stater, 17403
        • Wellspan York Hospital
    • Tennessee
      • Brentwood, Tennessee, Forenede Stater, 37027
        • HCA Tristar
      • Knoxville, Tennessee, Forenede Stater, 37920
        • UTMC Knoxville
      • Nashville, Tennessee, Forenede Stater, 37203
        • Ascension Saint Thomas Hospital
    • Texas
      • Dallas, Texas, Forenede Stater, 75235
        • Parkland Hospital
      • Fort Worth, Texas, Forenede Stater, 76104
        • Texas Health Harris Methodist Hospital
      • San Antonio, Texas, Forenede Stater, 78229
        • Methodist Main Hospital
      • Temple, Texas, Forenede Stater, 76508
        • Baylor Scott & White - Temple
    • Virginia
      • Falls Church, Virginia, Forenede Stater, 22042
        • Inova Fairfax
    • West Virginia
      • Charleston, West Virginia, Forenede Stater, 25304
        • Charleston Area Medical Center
      • Morgantown, West Virginia, Forenede Stater, 26506
        • West Virginia University Ruby Memorial Hospital
    • Wisconsin
      • Milwaukee, Wisconsin, Forenede Stater, 53215
        • Aurora Saint Luke's Medical Center
      • Lille, Frankrig
        • CHU Lille
      • Lyon, Frankrig
        • Hôpital Louis Pradel
      • Marseille, Frankrig
        • Hôpital Nord Marseille
      • Marseille, Frankrig
        • AP-HM Hopital La Timone
      • Basel, Schweiz
        • Universitaetsspital Basel
      • Bern, Schweiz
        • Universitätsspital Bern
      • Lucerne, Schweiz
        • Luzerner Kantonsspital
      • Madrid, Spanien
        • Hopital Clinico Universitario San Carlos
      • Augsburg, Tyskland
        • University Hospital Augsburg
      • Bad Krozingen, Tyskland
        • Universitäts-Herzzentrum Bad Krozingen
      • Berlin, Tyskland
        • Charité Campus Virchow Clinic - Klinik fuer Radiologie
      • Berlin, Tyskland
        • Unfall Krankenhaus Berlin
      • Cologne, Tyskland
        • University Hospital Cologne
      • Dresden, Tyskland
        • HerzZentrum Dresden Universitaetsklinik
      • Düsseldorf, Tyskland
        • Universitaetsklinikum Dὒsseldorf
      • Essen, Tyskland
        • Universitaetsklinikum Essen
      • Essen, Tyskland
        • Elisabeth Hospital GmbH
      • Frankfurt, Tyskland
        • CCB Frankfurt
      • Hamburg, Tyskland
        • Universitaetsklinikum Hamburg Eppendorf
      • Heidelberg, Tyskland
        • University Hospital - Heidelberg
      • Kaiserslautern, Tyskland
        • Westpfalz Klinikum
      • Munich, Tyskland
        • Klinikum rechts der Isar (TUM)
      • Munich, Tyskland
        • Ludwig Maximilians-University
      • Regensburg, Tyskland
        • University Hospital Regensburg
      • Villingen-Schwenningen, Tyskland
        • Schwarzwald-Baar-Klinikum

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Age at enrollment ≥ 18 years

  2. Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery, as confirmed by CTPA, pulmonary angiography, or other imaging modality

  3. RV dysfunction, as defined as one or more of the following: RV/LV ratio ≥ 0.9 or RV dilation or hypokinesis

  4. At least two additional risk factors, identified by at least one measure in two separate categories noted below:

    a. Hemodynamic: i. SBP 90-100mmHg ii. Resting heart rate > 100 bpm b. Biomarker: i. Elevated* cardiac troponin (troponin I or troponin T, conventional or high sensitivity) ii. Elevated* BNP or NT-proBNP iii. Elevated venous lactate ≥2 mmol/L * Elevated, meaning at or above the upper limit of normal, per local standards for the assay used c. Respiratory: i. O2 saturation < 90% on room air ii. Supplemental O2 requirement ≥ 4 L/min iii. Respiratory rate ≥ 20 breaths/min iv. mMRC score > 0

  5. Symptom onset within 14 days of confirmed PE diagnosis

  6. Willing and able to provide informed consent

Exclusion Criteria:

  1. Unable to be anticoagulated with heparin, enoxaparin or other parenteral antithrombin

  2. Presentation with hemodynamic instability* that meets the high-risk PE definition in the 2019 ESC Guidelines1, including ANY of the following

    1. Cardiac arrest OR
    2. Systolic BP < 90 mmHg or vasopressors required to achieve a BP ≥ 90 mmHg despite adequate filling status, AND end-organ hypoperfusion OR
    3. Systolic BP < 90 mmHg or systolic BP drop ≥ 40 mmHg, lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolemia, or sepsis * Patients who are stable at time of screening or randomization (i.e., SBP ≥ 90 mmHg and adequate organ perfusion without catecholamine or vasopressor infusion) may be included despite initial presentation including temporary, low-dose catecholamines or vasopressors, or temporary fluid resuscitation.
  3. Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated

  4. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention (e.g., inability to navigate to target location, clot limited to segmental/subsegmental distribution, predominately chronic clot)

  5. End stage medical condition with life expectancy < 3 months, as determined by the Investigator

  6. Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study

  7. Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis, per 2019 ESC Guidelines1

  8. If objective testing was performed*, estimated RV systolic pressure > 70 mmHg on standard of care echocardiography * If clinical suspicion of acute-on-chronic PE, chronic obstruction, or chronic thromboembolism, echocardiographic estimated RVSP must be confirmed ≤70 mmHg to meet eligibility. Pressure assessment not required if Investigator attests to absence of such clinical suspicion

  9. Administration of advanced therapies (thrombolytic bolus, thrombolytic drip/infusion, catheter-directed thrombolytic therapy, mechanical thrombectomy, or ECMO) for the index PE event within 30 days prior to enrollment

  10. Ventricular arrhythmias refractory to treatment at the time of enrollment

  11. Known to have heparin-induced thrombocytopenia (HIT)

  12. Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments). This includes a contraindication to use of FlowTriever System per local approved labeling

  13. Subject is currently pregnant

  14. Subject has previously completed or withdrawn from this study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: FlowTriever

Mechanical thrombectomy for pulmonary embolism using the FlowTriever System.

Mechanical Thrombectomy for pulmonary embolism

Aktiv komparator: Anticoagulation

Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.

Anticoagulants are a group of medications that decrease your blood's ability to clot.

Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.

Anticoagulants are a group of medications that decrease your blood's ability to clot.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Composite clinical endpoint constructed as a win ratio, a hierarchy of the following, which are assessed post-randomization:
Tidsramme: through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
  • All-cause mortality by 30 days, or
  • Clinical deterioration, defined by hemodynamic or respiratory worsening, through discharge or up to 30 days after randomization, whichever is sooner, or
  • All-cause hospital re-admission by 30 days, or
  • Bailout therapy, either after a deterioration or after documented failure to progress, through discharge or up to 30 days after randomization, whichever is sooner, or
  • Change in Dyspnea, by mMRC from Baseline to the 48-hour visit
through discharge or 30 days, whichever is sooner / dyspnea at 48 hours

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Alle årsager og PE-relateret dødelighed
Tidsramme: Ved 30 og 90 dage
Ved 30 og 90 dage
Alle årsager og PE-relaterede genindlæggelser
Tidsramme: Ved 30 og 90 dage
Ved 30 og 90 dage
6 minutters gåafstand
Tidsramme: Ved 1-måneders besøg
Ved 1-måneders besøg
RV/LV-forhold
Tidsramme: Ved det 48 timer lange besøg
Ved det 48 timer lange besøg
Post-PE Impairment Diagnosis (PPEI)
Tidsramme: Gennem det 3-måneders besøg
Gennem det 3-måneders besøg
Composite clinical endpoint constructed as a win ratio hierarchy of the following three components, assessed post randomization:
Tidsramme: up to 30 days
  • All-cause mortality, by 30 days, or
  • Clinical deterioration defined by hemodynamic or respiratory worsening, through discharge or up to 30 days after randomization, whichever is sooner, or
  • All-cause readmission, by 30 days
up to 30 days
Clinical deterioration
Tidsramme: Through discharge or up to 30 days after randomization, whichever is sooner

defined by hemodynamic or respiratory worsening

Through discharge or up to 30 days after randomization, whichever is sooner
Bailout therapy
Tidsramme: Through discharge or up to 30 days after randomization, whichever is sooner

either after a deterioration or after documented failure to progress,

Through discharge or up to 30 days after randomization, whichever is sooner
Major Bleeding, defined by the Bleeding Academic Research Consortium (BARC), level 3b, 3c, 5a, or 5b
Tidsramme: At 30 and 90 days

3b: Overt bleeding plus hemoglobin drop of ≥ 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid); bleeding requiring intravenous vasoactive agents 3c: Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal), subcategories confirmed by autopsy or imaging or lumbar puncture, intraocular bleed compromising vision.

5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious 5b: Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation

At 30 and 90 days
Dyspnea severity by mMRC score
Tidsramme: At the 48-hour, 1-month, and 3-month visits

0, no breathlessness except on strenuous exercise;

  • 1, shortness of breath when hurrying on the level or walking up a slight hill;
  • 2, walks slower than people of same age on the level because of breathlessness or has to stop to catch breath when walking at their own pace on the level;
  • 3, stops for breath after walking ∼100 m or after few minutes on the level; and
  • 4, too breathless to leave the house, or breathless when dressing or undressing
At the 48-hour, 1-month, and 3-month visits
PE-related quality of life, by PEmb-QoL
Tidsramme: At the 1- and 3-month visits

Pulmonary Embolism Quality of Life: (higher = better)

At the 1- and 3-month visits
General health-related quality of life, by EQ-5D-5L
Tidsramme: At the 1- and 3-month visits

Higher score = worse

At the 1- and 3-month visits

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Ledende efterforsker: Jay Giri, MD, Penn Medicine
  • Ledende efterforsker: Bernhard Gebauer, MD, Charité University Hospital Berlin
  • Ledende efterforsker: Felix Mahfoud, MD, Universitaetsspital Basel
  • Ledende efterforsker: Frances Mae West, MD, Jefferson Health

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. november 2023

Primær færdiggørelse (Faktiske)

30. juli 2026

Studieafslutning (Faktiske)

30. oktober 2026

Datoer for studieregistrering

Først indsendt

15. september 2023

Først indsendt, der opfyldte QC-kriterier

20. september 2023

Først opslået (Faktiske)

28. september 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner